Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Cancer Research
|
May 25, 2019
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, et al.
Breast Cancer Research and Treatment
|
March 16, 2016
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano, Gilles Romieu, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H J Kruit, Stefan Suciu, Brigitte Dreno, et al.
Breast Cancer Research and Treatment
|
March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A Limentani, Mario Campone, Thierry Dorval, et al.
Journal of Translational Medicine
|
March 3, 2005
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Bernard Escudier, Thierry Dorval, Nathalie Chaput, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2005
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells
Nicolas van Baren, Marie-Claude Bonnet, Brigitte Dréno, et al.
International Journal of Cancer
|
June 10, 2005
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
Wim H J Kruit, Heidi H van Ojik, Vincent G Brichard, et al.
Nature Reviews. Drug Discovery
|
December 15, 2021
IMI European Lead Factory - democratizing access to high-throughput screening
Philip S Jones, Sylviane Boucharens, Stuart P McElroy, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Cancer Research
|
May 25, 2019
Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress
Lucy A Young, Lenka Oplustil O'Connor, Christelle de Renty, et al.
Breast Cancer Research and Treatment
|
March 16, 2016
A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
Giuseppe Curigliano, Gilles Romieu, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2013
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H J Kruit, Stefan Suciu, Brigitte Dreno, et al.
Breast Cancer Research and Treatment
|
March 20, 2016
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Steven A Limentani, Mario Campone, Thierry Dorval, et al.
Journal of Translational Medicine
|
March 3, 2005
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Bernard Escudier, Thierry Dorval, Nathalie Chaput, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2005
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells
Nicolas van Baren, Marie-Claude Bonnet, Brigitte Dréno, et al.
International Journal of Cancer
|
June 10, 2005
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma
Wim H J Kruit, Heidi H van Ojik, Vincent G Brichard, et al.
Nature Reviews. Drug Discovery
|
December 15, 2021
IMI European Lead Factory - democratizing access to high-throughput screening
Philip S Jones, Sylviane Boucharens, Stuart P McElroy, et al.
Page
of 4